Corporate Finance

National Safety Apparel appoints its first non-family CEO in 90 years, signaling a strategic pivot to professionalized growth and M&A in a dynamic PPE market.

With a $7M seed round and backing from IT Glue's founder, Lexful is challenging legacy systems by building an AI-native documentation platform from the ground up.

When a stock is halted, the real story isn't the frozen price. It's the frantic activity that came before and the systemic risks it reveals for global investors.

Homeowners are tapping equity at the highest Q1 rate since 2021, not by refinancing, but through a surge in second liens not seen in two decades.

The pest control specialist's Nasdaq debut is more than a ticker change. It’s a calculated gambit to tap U.S. capital and scale a resilient, niche industry.

Griffon Corporation is offloading its AMES Australasia unit, but this is no fire sale. It’s a calculated JV that nets cash now and retains future upside.

With a new $4.3B war chest, Hunter Point Capital is evolving from a GP stakes firm into a scaled solutions platform, meeting a critical need for liquidity.

A major stock conversion aims to save Alpha Modus from Nasdaq delisting. Is it a savvy financial maneuver or a last-ditch effort for its AI ambitions?

BioCardia secures a crucial $4.4M, extending its runway for a key Japan submission. But a closer look reveals a high-stakes bet on future warrant exercises.

As rural hospitals face financial collapse, a new wave of AI-powered technology is proving it can stabilize finances and preserve access to essential care.

TelyRx just filled its millionth prescription, but the real story isn't the number. It's the 'operational innovation' of its cash-pay model that's disrupting healthcare.

Patagonia Gold celebrates first gold from its Calcatreu mine, a major operational win that ignites Argentina's Rio Negro economy amid deep-seated local dissent.

VENU's $50M sale-leaseback fuels a rapid expansion. But is its innovative financial model a new blueprint for growth or a high-stakes bet on the future?

As the Pentagon scrambles for battle-tested autonomous weapons, a new partnership promises to deliver. But is fast-tracking foreign tech the answer or a risky bet?

Ares Capital, a giant in middle-market finance, just opened a new $1B funding spigot. Is this a blueprint for the BDC industry or a sign of cheaper capital for American businesses?

With a new CMO known for getting drugs approved, Protego Biopharma is betting big on its novel approach to treating a devastating rare disease.

A silent demographic cliff threatens trillions in assets. With 75% of advisors unprepared for transition, a new framework argues for legacy over exit.

Rokid's $4M Makuake success isn't just a record; it's a signal. With AI translation as the killer app, are smart glasses finally moving from niche to necessary?

The Stoneport Commodity ETF is liquidating after just seven months. Its story reveals the harsh, unsentimental system governing the competitive ETF market.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?